A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes.

Authors :: Riegersperger M
Plischke M
Jallitsch-Halper A
Steinhauser C
Födinger M
Winkelmayer WC
Dunkler D
Sunder-Plassmann G
Source :: PloS one [PLoS One] 2019 Jul 02; Vol. 14 (7), pp. e0218709. Date of Electronic Publication: 2019 Jul 02 (Print Publication: 2019).
Publication Year :: 2019
Abstract: Trial Registration: PEP Study: Ethics committee N° 393/2004, EudraCT 2004-004209-98. PEP-X Study: Ethics committee amendment application N° 154/01/2008. ClinicalTrials.gov NCT03751332.<br />Competing Interests: This commercial affiliation (in the form of salaries from Astellas Pharma Inc. for MP, research/travel funds for MR, and an unrestricted grant for GSP) does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products.

Full Text Access

Tools